Role and Activation Status of IRS1/2 in IL-4-induced Protection from Cell Death.
IRS1/2 在 IL-4 诱导的细胞死亡保护中的作用和激活状态。
基本信息
- 批准号:8006677
- 负责人:
- 金额:$ 3.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2011-12-31
- 项目状态:已结题
- 来源:
- 关键词:ApoptosisApoptoticBasophilsBreast Cancer CellCell CycleCell DeathCell ProliferationCellsCyclinsDataIRS1 geneIRS2 geneImmune responseInterleukin-4Malignant NeoplasmsMediatingModelingMolecularPathway interactionsPatientsPhosphorylationProteinsPublishingRegulationResistanceRoleSTAT proteinSTAT6 geneSignal PathwaySystemT-LymphocyteTestingbasec-myc Genescell typechemotherapycytokinedesigneosinophilin vivomast cellneoplastic cellpreventprogramspublic health relevanceresponsetherapeutic targettumortumor progression
项目摘要
DESCRIPTION (provided by applicant): IL-4 is a cytokine with many functions that is produced mainly by TH2 cells, basophils, and mast cells, but is also expressed by NK T cells, gamma/delta T cells, and eosinophils. There are two main signaling pathways activated by IL-4; the STAT6, signal transducers and activators of transcription, pathway that results in expression of IL-4-responsive genes and the IRS1/2 signaling pathway that influences cellular proliferation and survival. Having a decreased Th1/Th2 ratio is observed in many cancers and although this impairs cytotoxity against tumors, cytokines such as IL-4 do not act simply by modulating the immune response. IL-4 can also act directly on many tumor cell types to prevent apoptosis. Both the STAT6 pathway and the IRS1/IRS2 proteins have been associated with cancer due to their impact on regulation of anti-apoptotic proteins and control of cell proliferation. Most studies have focused solely on the contribution of the STAT6 pathway and its ability to upregulate Bcl-xL. Fewer studies have examined the role and activation status of IRS1 or IRS2 in IL-4-induced protection from cell-death. Based on the published findings and our preliminary data, we propose that IRS1 and IRS2 differentially contribute to the responsiveness of cells to chemotherapy. We have found that expression of IRS1 leads to enhanced sensitivity to chemotherapy-induced cell death in 32D cells. We hypothesize that these effects are mediated through the differential phosphorylation of IRS1 and IRS2, and the activation or inactivation of downstream regulators of the cell cycle (i.e. c-myc, p27, cyclins, and CDKs) and apoptosis (i.e. Bcl- xL, cFlipL, pAkt). Two specific aims are designed to test this hypothesis. Aim 1 is to define the role of IRS1 and IRS2 in sensitivity to chemotherapy in the model 32D cell system. Aim 2 is to analyze the role of IRS1 and IRS2 in breast cancer cell resistance to chemotherapy-induced cell death. The ability to antagonize enhanced STAT6 and/or IRS1/2 activation may provide therapeutic targets to efficiently inhibit cancer progression. Understanding the molecular programming of a cell may also allow for the better prediction of a patient's response to treatment.
描述(由申请人提供):IL-4是一种具有多种功能的细胞因子,主要由TH2细胞、嗜碱性细胞和肥大细胞产生,但也由NK T细胞、γ / δ T细胞和嗜酸性细胞表达。IL-4激活了两种主要的信号通路;STAT6,转录的信号转导和激活因子,导致il -4应答基因表达的途径,以及影响细胞增殖和存活的IRS1/2信号通路。在许多癌症中观察到Th1/Th2比率降低,尽管这损害了对肿瘤的细胞毒性,但细胞因子如IL-4并不仅仅通过调节免疫反应起作用。IL-4还能直接作用于多种肿瘤细胞,防止细胞凋亡。STAT6通路和IRS1/IRS2蛋白都与癌症有关,因为它们对抗凋亡蛋白的调控和细胞增殖的控制有影响。大多数研究只关注STAT6通路的作用及其上调Bcl-xL的能力。很少有研究检测IRS1或IRS2在il -4诱导的细胞死亡保护中的作用和激活状态。基于已发表的研究结果和我们的初步数据,我们提出IRS1和IRS2对细胞对化疗的反应性有不同的贡献。我们发现,IRS1的表达导致32D细胞对化疗诱导的细胞死亡的敏感性增强。我们假设这些作用是通过IRS1和IRS2的差异磷酸化,以及细胞周期下游调节因子(如c-myc、p27、cyclins和CDKs)和细胞凋亡(如Bcl- xL、cFlipL、pAkt)的激活或失活介导的。为了验证这一假设,设计了两个具体目标。目的1是明确IRS1和IRS2在32D模型细胞系统中对化疗敏感性的作用。目的2分析IRS1和IRS2在乳腺癌细胞抵抗化疗诱导的细胞死亡中的作用。抗STAT6和/或IRS1/2激活增强的能力可能为有效抑制癌症进展提供治疗靶点。了解细胞的分子程序也可以更好地预测病人对治疗的反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Holly Alicia Porter其他文献
Holly Alicia Porter的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Mechanisms that underlie the life/death decisions in a cell that activated apoptotic caspases
细胞中激活凋亡半胱天冬酶的生/死决策的机制
- 批准号:
10607815 - 财政年份:2023
- 资助金额:
$ 3.24万 - 项目类别:
Nuclear and chromatin aberrations during non-apoptotic cell death in C. elegans and mammals
线虫和哺乳动物非凋亡细胞死亡过程中的核和染色质畸变
- 批准号:
10723868 - 财政年份:2023
- 资助金额:
$ 3.24万 - 项目类别:
Non-apoptotic functions of caspase-3 in neural development
Caspase-3在神经发育中的非凋亡功能
- 批准号:
10862033 - 财政年份:2023
- 资助金额:
$ 3.24万 - 项目类别:
Apoptotic Donor Leukocytes to Promote Kidney Transplant Tolerance
凋亡供体白细胞促进肾移植耐受
- 批准号:
10622209 - 财政年份:2023
- 资助金额:
$ 3.24万 - 项目类别:
Design of apoptotic cell mimetic anti-inflammatory polymers for the treatment of cytokine storm
用于治疗细胞因子风暴的模拟凋亡细胞抗炎聚合物的设计
- 批准号:
22H03963 - 财政年份:2022
- 资助金额:
$ 3.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
- 批准号:
10537709 - 财政年份:2022
- 资助金额:
$ 3.24万 - 项目类别:
Activation of non-apoptotic cell death by the DNA damage response
DNA 损伤反应激活非凋亡细胞死亡
- 批准号:
10388929 - 财政年份:2022
- 资助金额:
$ 3.24万 - 项目类别:
Environmental Carcinogens Induce Minority MOMP to Initiate Carcinogenesis in Lung Cancer and Mesothelioma whileMaintaining Apoptotic Resistance via Mcl-1
环境致癌物诱导少数 MOMP 引发肺癌和间皮瘤的癌变,同时通过 Mcl-1 维持细胞凋亡抵抗
- 批准号:
10356565 - 财政年份:2022
- 资助金额:
$ 3.24万 - 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
- 批准号:
10708827 - 财政年份:2022
- 资助金额:
$ 3.24万 - 项目类别:
Targeting apoptotic cells to enhance radiotherapy
靶向凋亡细胞以增强放射治疗
- 批准号:
10538071 - 财政年份:2022
- 资助金额:
$ 3.24万 - 项目类别:














{{item.name}}会员




